XOMA Royalty Corporation

NasdaqGM:XOMA Rapport sur les actions

Capitalisation boursière : US$354.3m

XOMA Royalty Croissance future

Future contrôle des critères 5/6

XOMA Royalty devrait augmenter ses bénéfices et ses revenus de 78% et de 31.3% par an respectivement, tandis que le BPA devrait croître de croître de 78.6% par an.

Informations clés

78.0%

Taux de croissance des bénéfices

78.6%

Taux de croissance du BPA

Biotechs croissance des bénéfices28.4%
Taux de croissance des recettes31.3%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour08 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

Oct 15

News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts

Aug 14
News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts

Health Check: How Prudently Does XOMA Royalty (NASDAQ:XOMA) Use Debt?

Aug 02
Health Check: How Prudently Does XOMA Royalty (NASDAQ:XOMA) Use Debt?

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

Jun 29

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Apr 03
Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Sep 01
Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Aug 11
Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Aug 04

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

May 08
Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

Xoma Gets The Spotlight

Sep 02

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Aug 20
Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

May 13
We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

May 11
Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

XOMA EPS misses by $0.55, misses on revenue

May 06

XOMA gets milestone payment from Janssen Biotech

May 03

XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Mar 17
XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be

Mar 16
Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be

Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?

Mar 09
Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?

Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?

Feb 02
Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?

XOMA: A Royalty Aggregator To Watch

Jan 04

XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?

Dec 29
XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?

XOMA prices $22M offering of series A cumulative perpetual preferred stock

Dec 11

Could The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Tell Us Something Useful?

Dec 01
Could The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Tell Us Something Useful?

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:XOMA - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/2026493N/AN/A3
12/31/202536-7N/AN/A3
12/31/202428-6N/AN/A3
9/30/202422-35-15-15N/A
6/30/202415-24-8-8N/A
3/31/20246-42-13-18N/A
12/31/20235-46-18-18N/A
9/30/20234-32-18-18N/A
6/30/20234-31-20-20N/A
3/31/20233-30-14-17N/A
12/31/20226-23-13-13N/A
9/30/202240104222N/A
6/30/202241103622N/A
3/31/202241123623N/A
12/31/20213882323N/A
9/30/2021301-1110N/A
6/30/2021296-310N/A
3/31/2021296-211N/A
12/31/20202991010N/A
9/30/20202-13-12-12N/A
6/30/202011-9-18-5N/A
3/31/202011-10-25-6N/A
12/31/201918-2-200N/A
9/30/201920-2-181N/A
6/30/201912-8-27-5N/A
3/31/201913-6-21-6N/A
12/31/20185-13-28-13N/A
9/30/20189-11-30-15N/A
6/30/2018449N/A18N/A
3/31/20185318N/A13N/A
12/31/2017536N/A3N/A
9/30/201748-11N/A15N/A
6/30/201712-39N/A-28N/A
3/31/20172-61N/A-32N/A
12/31/20166-54N/A-34N/A
9/30/201653-11N/A-12N/A
6/30/2016551N/A-19N/A
3/31/201657-7N/A-23N/A
12/31/201555-21N/A-31N/A
9/30/201512-53N/A-77N/A
6/30/201515-67N/A-74N/A
3/31/201518-55N/A-74N/A
12/31/201419-38N/A-78N/A
9/30/201427-83N/A-68N/A
6/30/201428-99N/A-65N/A
3/31/201429-104N/A-60N/A
12/31/201335-124N/A-46N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: XOMA devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.6% ).

Bénéfices vs marché: XOMA devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: XOMA devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de XOMA ( 31.3% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de XOMA ( 31.3% par an) devrait croître plus rapidement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de XOMA devrait être élevé dans 3 ans


Découvrir les entreprises en croissance